The primary efficacy analysis was executed on an intention-to-treat basis, with each dosage compared with placebo, as a time-to-event evaluation from randomization to the first occurrence of any part of the primary composite end point . The analysis of secondary end points proceeded in a hierarchical fashion, starting with cardiovascular death and death from any cause then; the additional end points listed were evaluated on an exploratory basis above. An exploratory analysis of the combined results observed with the two ticagrelor doses, in comparison with placebo, was prespecified. Security analyses included all the patients who all underwent randomization and received at least one dose of study medication.(8 a.m. – 10 a.m. Sat. ‘The 48-week PROGRESS study results, without definitive, suggest that the nucleoside-sparing HIV routine of Kaletra and Isentress could be an alternative solution treatment option for individuals new to HIV therapy, in comparison with a typical HIV regimen.D., professor of medicine, head of the Tropical and Infectious Disease Division at the University Medical center Center of Montpellier, France, and a presenting author of the PROGRESS research. HIV treatment regimens are typically drawn from approximately 20 approved antiretroviral medicines in six classes.